Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 55 results for ng191

  1. In people with suspected COVID-19-associated pulmonary aspergillosis (CAPA), what are the most accurate tests for diagnosing the infection and when should they be done?

    Recommendation ID NG191/12 Question In people with suspected COVID-19-associated pulmonary aspergillosis (CAPA), what are the most...

    Research recommendation
    Published
    17 December 2021

  2. What is the effectiveness, cost effectiveness and safety of the combination of casirivimab and imdevimab for treating COVID-19 in people with particular clinical characteristics (for example, people who are seropositive, of unknown serostatus, immunocompromised, or with specific comorbidities and within both the seropositive and seronegative groups, according to vaccination status or history of natural infection)?

    Recommendation ID NG191/8 Question What is the effectiveness, cost effectiveness and safety of the combination of casirivimab and...

    Research recommendation
    Published
    21 October 2021

  3. What are the possible outcomes for people who are critically ill and have COVID-19-associated pulmonary aspergillosis (CAPA)?

    Recommendation ID NG191/11 Question What are the possible outcomes for people who are critically ill and have COVID-19-associated...

    Research recommendation
    Published
    17 December 2021

  4. What is the effectiveness and safety of standard-dose compared with intermediate-dose pharmacological venous thromboembolism (VTE) prophylaxis for people with COVID-19, with or without additional risk factors for VTE?

    Recommendation ID NG191/1 Question What is the effectiveness and safety of standard-dose compared with intermediate-dose pharmacological

    Research recommendation
    Published
    10 August 2021

  5. What is the clinical effectiveness and safety of vitamin D for treating COVID-19 in children, young people and adults?

    Recommendation ID NG191/19 Question What is the clinical effectiveness and safety of vitamin D for treating COVID-19 in children, young

    Research recommendation
    Published
    14 July 2022

  6. What are the clinical and cost effectiveness, and the safety, of specific antifungal treatments for treating suspected or confirmed COVID-19-associated pulmonary aspergillosis (CAPA), and the optimal treatment duration? When should treatment be started, stopped or modified?

    Recommendation ID NG191/14 Question What are the clinical and cost effectiveness, and the safety, of specific antifungal treatments for

    Research recommendation
    Published
    9 March 2022

  7. What is the efficacy and safety of COVID-specific antiviral drugs in combination with other COVID-specific antiviral drugs or COVID-specific neutralising monoclonal antibodies in people who do not need supplemental oxygen and are within 7 days of symptom onset?

    Recommendation ID NG191/16 Question What is the efficacy and safety of COVID-specific antiviral drugs in combination with other...

    Research recommendation
    Published
    9 March 2022

  8. What is the efficacy and safety of remdesivir for people who have been vaccinated against COVID-19?

    Recommendation ID NG191/17 Question What is the efficacy and safety of remdesivir for people who have been vaccinated against COVID-19

    Research recommendation
    Published
    9 March 2022

  9. What is the effectiveness of awake body positioning in improving outcomes for people in hospital with COVID-19 who are not intubated and have higher oxygen needs?

    Recommendation ID NG191/18 Question What is the effectiveness of awake body positioning in improving outcomes for people in hospital with

    Research recommendation
    Published
    9 March 2022

  10. COVID-19 rapid guideline: managing suspected or confirmed pneumonia in adults in the community (NG165)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

    COVID-19 rapid guideline
    Last updated
    23 April 2020

  11. COVID-19 rapid guideline: acute myocardial injury (NG171)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

    COVID-19 rapid guideline
    Last updated
    2 February 2021

  12. COVID-19 rapid guideline: acute kidney injury in hospital (NG175)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

    COVID-19 rapid guideline
    Published
    6 May 2020

  13. COVID-19 rapid guideline: antibiotics for pneumonia in adults in hospital (NG173)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

    COVID-19 rapid guideline
    Last updated
    9 October 2020

  14. COVID-19 rapid guideline: reducing the risk of venous thromboembolism in over 16s with COVID-19 (NG186)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

    COVID-19 rapid guideline
    Published
    20 November 2020

  15. COVID-19 rapid guideline: critical care in adults (NG159)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

    COVID-19 rapid guideline
    Last updated
    12 February 2021